From the Editor

Unresolved questions about the specialty lurk in the cortex of psychiatrists

Author and Disclosure Information

 

References

Why don’t people realize that today’s research is tomorrow’s treatment? That research is not a luxury but an ongoing necessity? Why don’t more freshly minted, young psychiatrists pursue a career in research to accelerate the pace of progress about the biological causes and treatments of serious psychiatric disorders? Why aren’t there more incentives to grow the next generation of psychiatric discoverers and Nobel laureates? Why don’t clinicians support research by referring patients to clinical trials of medications or to National Institutes of Health-funded investigations of the neurobiology of psychiatric disorders?

Are these just rhetorical questions?
Some might sound that way. But they are not. These questions are brewing inside the hearts and minds of many psychiatrists, although only a few seem determined to relentlessly seek answers on which medical science and society can act.

We should collectively pose these “why” questions and not accept long-winded, hollow answers. We need to foster the winds of change—not resign ourselves to winds in which answers blow about but, ultimately, disappear.

Pages

Recommended Reading

VIDEO: Loss of function in Rab10 gene cuts Alzheimer’s risk by up to 40%
MDedge Psychiatry
VIDEO: Medicare pays billions for potentially avoidable hospital admissions in dementia patients
MDedge Psychiatry
Gay and bisexual male high schoolers have high injected drug use
MDedge Psychiatry
Medicare annual wellness visit remains underused
MDedge Psychiatry
FDA updates warning label for systemic fluoroquinolones
MDedge Psychiatry
VIDEO: Proposed Alzheimer’s funding boost could mean wider research scope
MDedge Psychiatry
VIDEO: Alzheimer’s anti-tau drug fails, but shows hint of effect when taken alone
MDedge Psychiatry
Different approaches can combat negative online reviews
MDedge Psychiatry
Disordered sleep: Ask the right questions to reveal this hidden confounder
MDedge Psychiatry
Alzheimer’s anti-tau drug fails phase III, but posts some benefit in monotherapy subanalysis
MDedge Psychiatry